EUVIMEDEUVIMED entdecken
Crossref

Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs

Cathia Soulie iD, Rachid Agher, Antoine Fauchois, Basma Abdi iD, Marc Wirden iD, Elisa Teyssou, Sophie Sayon, Christine Katlama, Marc-Antoine Valantin, Roland Tubiana, Luminita Schneider, Antoine Faycal und 4 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Cathia Soulie und 15 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, laboratoire de vir…. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Reverse Transcriptase Inhibitors, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: ANRS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to determine how non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance profiles have changed over the last decade in people living with HIV (PLWHIV) experiencing virological failure on all antiretroviral treatments, including different NNRTIs. Materials and methods We analysed the use of the different NNRTIs in PLWHIV treated with antiretroviral drugs at an academic centre and the HIV NNRTI resistance profiles observed in cases of virological failure over the last 10 years (2014–23). We used the latest ANRS-MIE algorithm (v33; https://hivfrenchresistance.org/) to analyse the resistance mutation profiles of the HIV reverse transcriptase sequences.

Results

During this period, the frequency of NNRTI use remained high, fluctuating slightly between 43.5% (n = 1782/4094) and 39.9% (n = 1758/4421). The use of efavirenz (10.8%–1.5%), nevirapine (7.0%–1.2%), and etravirine (11.0%–1.1%) decreased, whereas the use of rilpivirine (14.7%–26.3%) and doravirine (available from 2018, rising to 9.7% in 2023) increased. These trends were statistically significant for etravirine (P = 0.033) and rilpivirine (P < 0.001). Resistance rates for efavirenz, nevirapine and rilpivirine remained above 15% (efavirenz: 17.3%–16.6%, nevirapine: 16.9%–15.4% and rilpivirine: 17.6%–16.1%). This reflects significant cross-resistance between these three NNRTIs. By contrast, resistance rates were lower for etravirine (7.8%–6.0%) and doravirine (4.9%–4.6%), probably due to differences in their resistance profiles and higher genetic barriers to resistance.

Conclusions

The NNRTI class of antiretroviral drugs remains widely used. Changes in the usage of drugs from this class have not altered the ecology of NNRTI resistance in antiretroviral drug-treated PLWHIV with virological failure during the studied period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralReverse Transcriptase InhibitorsAnti-HIV AgentsHIV-1Drug UtilizationHumansTreatment FailureCyclopropanesAlkynesMaleHIV Reverse TranscriptaseFemalePyridazinesNitrilesAdultRilpivirinePyridonesMiddle AgedNevirapineMutationBenzoxazinesAntiretroviral Therapy, Highly ActiveTriazolesPyrimidines

Substanzen

Reverse Transcriptase InhibitorsAnti-HIV AgentsCyclopropanesAlkynesetravirineHIV Reverse TranscriptaseefavirenzPyridazinesNitrilesRilpivirine

Autor:innen und Institutionen

  • INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, laboratoire de virologie, Sorbonne Université, Paris, France.
  • INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, service de maladies infectieuses, Sorbonne Université, Paris, France.

ORCID-Profile: Cathia Soulie, Basma Abdi, Marc Wirden, Romain Palich, Valérie Pourcher

Förderung

  • ANRS

Zitieren

APA

Soulie, C., Agher, R., Fauchois, A., Abdi, B., Wirden, M., Teyssou, E., Sayon, S., Katlama, C., Valantin, M. A., Tubiana, R., Schneider, L., Faycal, A., Palich, R., Pourcher, V., Marcelin, A. G., & Calvez, V. (2025). Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae458

Vancouver

Soulie C, Agher R, Fauchois A, Abdi B, Wirden M, Teyssou E, et al. Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae458

BibTeX
@article{Soulie2025,
  author = {Soulie, Cathia and Agher, Rachid and Fauchois, Antoine and Abdi, Basma and Wirden, Marc and Teyssou, Elisa and Sayon, Sophie and Katlama, Christine and Valantin, Marc-Antoine and Tubiana, Roland and Schneider, Luminita and Faycal, Antoine and Palich, Romain and Pourcher, Valérie and Marcelin, Anne-Geneviève and Calvez, Vincent},
  title = {Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae458}
}
Kostenlos starten →